Sagimet Posts 31c Quarterly Loss as Phase 3 R&D Spending Jumps 68%
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet reported a third-quarter loss of 31 cents a share, with the net loss widening to $19.1M as R&D spending jumped 68% on the AURORA Phase 3 acne trial. The company ended the quarter with $275.8M in cash and securities, before the October offering added roughly $107.5M net. That cash position is the key number here: it funds the Phase 3 program well past the first patient dosing disclosed in the October investor presentation, so dilution risk near term is low. The wider loss is the expected cost of running the trial, not a surprise deterioration in the business. The stock is trading near its 52-week high, so the bar for these numbers was high.
At the time of this announcement, SGMT was trading at $11.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $802.6M. The 52-week trading range was $4.50 to $11.45. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.